Matricelf
Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. Based in Ness Ziona.
Matricelf: net income sharply up (+19.4%), operating income sharply down (−96.9%), cash flow stable (+0.0%).
- Net income sharply upH1 2026
Net income: ₪−8M, vs. ₪−10M a year earlier, i.e. +19.4%.
- Operating income sharply downH1 2026
Operating income: ₪−19M, vs. ₪−10M a year earlier, i.e. −96.9%.
- Cash flow stableH1 2026
Operating cash flow: ₪−8M, vs. ₪−8M a year earlier, i.e. +0.0%.
What the market pays, vs. the sector
This company's valuation multiples history is being built day by day from now on.
P/E calculated on net income (trailing 12 months: last fiscal year + H1 2026 − same period a year earlier). Sector median: companies in the group tracked here. Prices: Yahoo Finance; market cap cross-checked with the Tel Aviv Stock Exchange for Israeli stocks. These ratios describe a price, not a value: none of them says whether the share is expensive or cheap.
Trades by executives and interested parties
11 filing(s) over 12 months · on shares: 1 increase(s) and 0 decrease(s) in holdings.
| Date | Holder | Security | Direction | Quantity | Price | |
|---|---|---|---|---|---|---|
| 24/04/2026 | Hakim Gil Director | Shares | Up | 27,262 | ₪2.75 | Maya › |
| 26/03/2026 | Tamar Harel Hadar Executive | Options | Up | 400,000 | — | Maya › |
| 26/03/2026 | Tamar Harel Hadar Interested party | Options | Up | 400,000 | — | Maya › |
| 18/09/2024 | Alon Sinai Director | Options | Up | 50,000 | — | Maya › |
| 18/03/2026 | Hakim Gil Director | Options | Up | 600,000 | — | Maya › |
| 18/03/2026 | Alon Sinai Director | Options | Up | 600,000 | — | Maya › |
| 18/03/2026 | Ron Mayron Director | Options | Up | 600,000 | — | Maya › |
| 18/03/2026 | Dvir Tal Director | Options | Up | 300,000 | — | Maya › |
| 18/03/2024 | Dvir Tal Director | Options | Up | 547,000 | — | Maya › |
| 04/11/2025 | Sami Sagol Interested party | Options | Down | 2,270,817 | — | Maya › |
| 06/01/2026 | Dvir Tal Director | Options | Up | 253,280 | — | Maya › |
Filings submitted on Maya (executives, directors, shareholders above 5%). An increase or decrease in holdings may come from a purchase or sale on the exchange, but also from a grant or exercise of options (price "—": grant with no price). Bonds excluded. For details, see the filing on Maya.
Follow earnings · WhatsApp group TA-125Details ▾
Every report from a TA-125 company, analyzed the same day: key figures and year-on-year change, analysis in brief, share price reaction. One daily summary during earnings season.
Join the TA-125 groupDetailed figures and history
Financial summary
| S1 2026 | S1 2025 | FY 2025 | |
|---|---|---|---|
| Total assets | 26 | 11 | 28 |
| Current assets | 17 | 6 | 23 |
| Non-current assets | 9 | 5 | 5 |
| Equity | 16 | 8 | 10 |
| of which minority interests | 0 | 0 | 0 |
| Current liabilities | 6 | 2 | 17 |
| Non-current liabilities | 4 | 1 | 0 |
| Revenue | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 |
| Operating income | −19 | −10 | −18 |
| Pre-tax income | −8 | −10 | −28 |
| Net income | −8 | −10 | −28 |
| Net income (attributable to shareholders) | −8 | −10 | −28 |
| Dividends paid | 0 | 0 | 0 |
| Operating cash flow | −8 | −8 | −15 |
In millions of shekels. The "H1" columns cover the first six months of the year.
Calculated from these figures
| S1 2026 | S1 2025 | FY 2025 | |
|---|---|---|---|
| Gross margin | — | — | — |
| Operating margin | — | — | — |
| Net margin | — | — | — |
| Current ratio (current assets / current liabilities) | 2,7 x | 2,7 x | 1,3 x |
| Equity / total assets | 62.8% | 75.5% | 36.2% |
The 5-year history, charts and cross-check models are coming for companies listed only in Tel Aviv: each new filing on Maya is kept and enriches the page.
Company overview
Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company's regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson's disease, and myocardial infarction, as well as for 3D bioprinting. The company has a strategic collaboration with Sheba Medical Center for the development and clinical advancement of its neural tissue implant product for the treatment of spinal cord injury; and CiRA Foundation for the development of regenerative manufacturing technologies and the evaluation of iPSC-based neural tissue engineering for therapeutic applications. The company was incorporated in 2019 and is based in Ness Ziona, Israel.
Source: official company profile (Yahoo Finance), summary. Website: matricelf.com
- Maya, Tel Aviv Stock Exchange: company page and reports
No dividend paid over the past five years (source: Yahoo Finance).